Multi-center, Open-Label, Single-Arm Study of Yondelis (trabectedin) for Subjects With Locally Advanced or Metastic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment. Phase III ET743-SAR-3002
A clinical trial of the investigational drug Yondelis, administered by intravenous infusion.
IRB Protocol #
Johnson & Johnson Pharmaceutical R & D, LLC
MEGHAN HOULIHAN at (720)848-1156 or MEGHAN.HOULIHAN@UCDENVER.EDU
University of Colorado Hospital University of Colorado Hospital
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last approximately 4 months. A follow up period will consist of a clinic visit. // Eligibility criteria include but are not limited to patients 18 years or older with advanced soft tissue sarcoma.Eligibility criteria include but are not limited to patients 18 years or older with advanced soft tissue sarcoma.